The Endocrine Society will begin a search for a new Chief Executive Officer following the announced departure of Kate Fryer, CAE, effective June 5, 2026. Fryer, who has led the global organization since 2021, leaves behind a tenure marked by a 10% increase in operating revenue and a near 20% growth in the Society’s investment portfolio, according to an official statement from the organization.
What were the primary achievements under Kate Fryer’s leadership?
During her five-year tenure, Fryer focused on expanding the Society’s reach through both clinical and academic channels. The organization launched JCEM Case Reports, a new journal aimed at providing practical insights for practitioners, and merged with the Association of Program Directors in Endocrinology, Diabetes and Metabolism (APDEM). According to the Endocrine Society, these moves were part of a broader effort to unify the endocrine community and accelerate scientific breakthroughs. Additionally, the Society re-envisioned the Hormone Foundation and established a partnership with Keystone to host boutique conferences specifically for basic scientists.
The Endocrine Society represents more than 18,000 members across 133 countries, making it the largest global organization dedicated to hormone research and clinical care.
How will the leadership transition affect the organization’s strategic goals?
The Board of Directors plans to conduct a formal search process to identify a successor capable of driving the Society’s next phase of growth. Carol Lange, PhD, President of the Board, stated that the organization is prioritizing leadership that can “unite, lead, and grow the endocrine community” to address global health challenges. The transition is scheduled for mid-2026, providing the Board with a long window to ensure continuity for the Society’s flagship programs, including the annual ENDO conference.
Why is the search for a new CEO critical for the future of endocrinology?
The incoming leader will inherit an organization deeply involved in addressing high-stakes public health issues. Endocrinologists currently lead research into diabetes, obesity, infertility, and hormone-related cancers—conditions that represent some of the most pressing health concerns identified by the Society. The new CEO will be responsible for maintaining the Society’s role as an advocate for evidence-based policies and sustaining the revenue streams necessary to support large-scale scientific meetings and research publications.
If you are a professional in the field, keep an eye on the Endocrine Society’s online newsroom for official updates regarding the search committee and potential recruitment milestones.
Frequently Asked Questions
- When will Kate Fryer step down as CEO?
Fryer’s departure is effective June 5, 2026. - Who is leading the search for the new CEO?
The Endocrine Society Board of Directors is managing the formal search process. - What is the primary focus of the Endocrine Society?
The Society focuses on hormone research, advancing clinical excellence, and advocating for health policies related to diabetes, obesity, and other endocrine disorders.
Are you tracking the latest developments in medical association leadership? Join the conversation by leaving a comment below or subscribing to our newsletter for updates on industry shifts and scientific research.
